uniQure (NASDAQ:QURE) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.
QURE has been the subject of a number of other reports. Zacks Investment Research upgraded uniQure from a “sell” rating to a “hold” rating and set a $9.25 target price for the company in a report on Wednesday, August 9th. Leerink Swann lifted their target price on uniQure from $19.00 to $26.00 in a report on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of uniQure in a report on Friday, November 24th. HC Wainwright started coverage on uniQure in a report on Friday. They issued a “buy” rating and a $28.00 target price for the company. Finally, Evercore ISI started coverage on uniQure in a report on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 target price for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. uniQure has a consensus rating of “Buy” and a consensus target price of $18.75.
Shares of uniQure (NASDAQ QURE) opened at $15.56 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64. uniQure has a 1-year low of $4.72 and a 1-year high of $21.35.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2017/12/03/valuengine-downgrades-uniqure-qure-to-sell.html.
uniQure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
What are top analysts saying about uniQure N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for uniQure N.V. and related companies.